Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension - Quiz - MDSpire

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • By

  • WenXia Li

  • RuRan Li

  • ShanShan Li

  • Zhen Li

  • JingSu Ma

  • Fei Wu

  • ChaoQin Chen

  • May 11, 2026

  • 0 min

Share

Original Source(s)

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • by WenXia Li, RuRan Li, ShanShan Li, Zhen Li, JingSu Ma, Fei Wu, ChaoQin Chen

  • May 11, 2026

Related Content

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease

Editorial: Polycystic ovarian syndrome in adolescence

AI Boosts Diabetic Eye Care Access

Recent study highlights how integrated AI-assisted DR screening in primary care clinics can improve access and decrease disparity

  • May 5, 2026

  • 3 min